Early Access — free while we kick the tires
EdgarHawk

Wahl Bryan

General Counsel

Officer
1 filing analyzed · 1 company · Latest 2026-03-19

Companies

Company Buys Sells Direction
Tarsus Pharmaceuticals, Inc. TARS 0 3 Net selling

Activity

March 2026
high
Sell
12,440 shares
$850,417
Significance 6/10

General Counsel Wahl Bryan sold 12,440 shares of TARS over 3 days at $68.36 avg price, reducing holdings by 16.3% to 64.0K shares

Bryan conducted 3 separate sales totaling 12,440 shares for $850,417.03 on consecutive trading days (March 17-19, 2026) at prices ranging from $67.00 to $69.42. The sales represent a 16.3% reduction in his pre-transaction holdings of 76,399 shares. TARS is a high-growth company (annual revenue growth of 146.7%) but remains unprofitable with recent quarter net income of $-12,585,000.00 against quarterly revenue of $118,697,000.00. The transaction occurred when the stock was trading -19.1% from its 52-week high of $82.51, while the company's market cap stands at $2,840,712,591.00. This substantial equity reduction by a General Counsel warrants attention in the context of ongoing operational losses and prior peak valuations.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access